% alzhub.org library filter
% Source: https://alzhub.org/research?author=Brunstein+F
% 4 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{teng2022-35696185,
  author  = {Teng, E. and Manser, P. T. and Pickthorn, K. and Brunstein, F. and Blendstrup, M. and Sanabria Bohorquez, S. and Wildsmith, K. R. and Toth, B. and others},
  title   = {{Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2022},
  doi     = {10.1001/jamaneurol.2022.1375},
  pmid    = {35696185},
  url     = {https://doi.org/10.1001/jamaneurol.2022.1375}
}

@article{monteiro2023-37643887,
  author  = {Monteiro, C. and Toth, B. and Brunstein, F. and Bobbala, A. and Datta, S. and Ceniceros, R. and Sanabria Bohorquez, S. M. and Anania, V. G. and others},
  title   = {{Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet}},
  journal = {Neurology},
  year    = {2023},
  doi     = {10.1212/wnl.0000000000207663},
  pmid    = {37643887},
  url     = {https://doi.org/10.1212/wnl.0000000000207663}
}

@article{salloway2018-30231896,
  author  = {Salloway, S. and Honigberg, L. A. and Cho, W. and Ward, M. and Friesenhahn, M. and Brunstein, F. and Quartino, A. and Clayton, D. and others},
  title   = {{Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)}},
  journal = {Alzheimer's research \& therapy},
  year    = {2018},
  doi     = {10.1186/s13195-018-0424-5},
  pmid    = {30231896},
  url     = {https://doi.org/10.1186/s13195-018-0424-5}
}

@article{monteiro2023-1c8f9366,
  author  = {Monteiro, C. and Toth, B. and Brunstein, F. and Bobbala, A. and Datta, S. and Ceniceros, R. and Sanabria Bohorquez, S. M. and Anania, V. G. and Wildsmith, K. R. and Schauer, S. P. and Lee, J. and Dolton, M. J. and Ramakrishnan, V. and Abramzon, D. and Teng, E. and {the Lauriet investigators}},
  title   = {{Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet}},
  journal = {Neurology},
  year    = {2023},
  doi     = {10.1212/wnl.0000000000207663},
  pmid    = {37643887},
  url     = {https://doi.org/10.1212/wnl.0000000000207663}
}